Abstract
Objectives To evaluate the potential clinical significance of serum autotaxin (ATX) level in patients with cancers of the digestive system. Design and methods Serum ATX activity was measured as the lysophospholipase D activity in patients with cancer of the esophagus ( n = 8), stomach ( n = 18), colorectum ( n = 21), biliary tract ( n = 19), or pancreas ( n = 103) and in patients with benign pancreatic diseases (n = 73). Results Among patients with various cancers of digestive system, increased serum ATX activity was predominantly observed among pancreatic cancer patients. Serum ATX activity was not increased in patients with chronic pancreatitis or pancreatic cysts. In the diagnosis of pancreatic cancer, the area under the receiver operating curve for serum ATX activity was 0.541 (95% CI, 0.435–0.648) for men and 0.772 (95% CI, 0.659–0.885) for women. No significant correlation was observed between serum ATX activity and CEA, CA19-9 or Dupan2 levels. Conclusion Serum ATX activity may be useful for identifying pancreatic cancer when used together with other serum markers of pancreatic cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
